Figure 1. TBP-TAFs Complex in Different
Cell Types (A) TFIID-enriched PC fractions (1 M NaCl) of different cell types were subjected to immunoprecipitation using affinity-purified anti-TBP polyclonal antibodies. The TBP-associated polypeptides were eluted by 1.0 M guanidine-HCl, tricholoracetic acid-precipitated, resolved by 6%-15% gradient SDS-PAGE, and stained by silver. Under these conditions, most of TBP and the antibodies remain bound to the protein A sepharose beads; therefore, only traces of both can be detected. The cell types used are indicated on top of each lane. The position of the core TAFs and molecular size markers are indicated on the sides, and TAFII105 is indicated by an arrow. . The immune complexes were processed as in (A). The asterisk indicates a polypeptide related to TAF II130, based on peptides microsequencing and cross-reactivity with TAF II130-specific antibody. Since its appearance is not consistent (compare with Figure 1A , lane 2), we assume that it is a breakdown product.
Tanese, and R. T., unpublished data), although some specific subunit of TFIID that may function as a geneselective coactivator in certain cells. quantitative differences have been observed in the levels of some of the smaller subunits in fractionated HeLa TFIID complex (Jacq et al., 1994) . However, to date, Results there has been no clear evidence for cell type-specific subunits of TFIID. A search for potential cell type-
TFIID Subunits in Different Human Cell Types
To test the possibility that some TFIID subunits might specific TAFs is likely to be complicated by the possibility that they would be present in substoichiometric be cell type-specific, we compared the composition of TBP-TAF complexes isolated from several human cell amounts relative to the core subunits. In addition, differences in the pattern of polypeptides associated with lines representing different tissues. For this purpose, nuclear extracts were first fractionated by phosphocel-TFIID isolated from different cell types or tissues may reflect alternative splicing, proteolytic processing, and lulose (PC) chromatography to separate TFIID from other TBP-TAF complexes (i.e., SL1 and TFIIIB). The posttranslation modifications of the ubiquitous subunits rather than novel cell type-specific TAFs. resulting 1.0 M NaCl PC fractions were subjected to anti-TBP affinity purification followed by SDS-polyIn an attempt to identify cell type-specific TAFs, we have isolated TFIID from several different cell lines by acrylamide gel electrophoresis (SDS-PAGE) analysis and staining with silver. As expected, the subunit comantibody affinity purification, using both anti-TBP and anti-TAF antibodies. Of the eight cell lines we tested, position and levels of the core TAFs relative to TBP were very similar among the different cell types examined only highly differentiated B cells revealed the presence of a novel large molecular mass polypeptide (105 kDa) ( Figure 1A ). By contrast, the TFIID complex isolated from Daudi B cells contained an additional polypeptide of that selectively associated with TFIID. Consistent with the notion of a cell type-specific TAF, this 105 kDa proapproximately 105 kDa ( Figure 1A , lane 3) that consistently coimmunoprecipitated with anti-TBP antibodies. tein appears to be present in substoichiometric amounts relative to the core TAFs. In order to characterize further This novel polypeptide is barely detectable in TFIID isolated from non-B cells such as the neuroblastoma SK-N, this putative cell type-specific subunit, we purified the 105 kDa polypeptide from B cells to homogeneity, isoglioblastoma U87, Jurkat and Hut78 T cells, and HeLa cervical carcinoma. lated a cDNA clone encoding this polypeptide, and compared its primary amino acid sequence with the known Association of this 105 kDa polypeptide with the TBPTAFs complex appears to be specific, since it can be TAFs. We also determined the levels of the 105 kDa protein and its corresponding mRNA in the different cell coimmunoprecipitated with TFIID using a different TBP antibody but not by mock immunoprecipitation in the types. Our results suggest that differentiated B cells contain a cell type-specific subunit of TFIID, TAFII105, absence of TBP antibodies ( Figure 1B ). We confirmed that the 105 kDa polypeptide is not a breakdown product that is homologous to one of the core subunits, providing evidence for a family of related TAFs that includes speof either TAFII250 or TAFII130 by Western blot analysis, using either anti-TAF II 250 or anti-TAF II 130 antibodies cialized members only found associated with TFIID in certain cell types. Interestingly, the overexpression of (data not shown). Daudi cells are characterized as Epstein-Barr virusthis putative cell type-specific TAF was able selectively to "squelch" the transcription of certain B cell-specific positive (EBV ϩ ) differentiated IgG-producing B cells. To determine whether the association of p105 with TBP genes, but not others, in transient transfection experiments. These results suggest that TAF II 105 is a cell typewas either EBV-or differentiation-related, we isolated TFIID from a less differentiated EBV ϩ B cell, Jy, and staining methods. Antibody affinity-purified TFIID complexes isolated from Daudi cells were subjected to SDSfound insignificant amounts of p105 relative to the other TFIID subunits ( Figure 1C ), suggesting that EBV gene PAGE and stained by both silver and Coomassie blue ( Figure 2B In order to characterize further this candidate cell typespecific TAF, we set out to isolate the corresponding for TFIID, to exclude the possibility that TAF II 105-containing complexes isolated from different cell types cDNA. For this purpose, we purified TFIID from nuclear extracts prepared from 2000 l of Daudi cells. TFIID was might merely reflect differential chromatographic properties. Both TBP and TAFII130 antibodies coimmunofirst fractionated over a PC column followed by anti-TBP affinity chromatography. The TFIID polypeptides were precipitated TAFII105 together with the other "core" TFIID subunits from Daudi nuclear extract (Figure 2A , resolved on a preparative SDS-PAGE gel and transferred onto nitrocellulose membrane, and the band corlanes 1 and 2). By contrast, only TBP and the core TAFs were isolated by TAF II 130 antibody from Jurkat nuclear responding to hTAF II 105 was excised and digested with either trypsin or Staphylococcus aureus V8 protease. extracts ( Figure 2A, lane 3) . To confirm these results, we also performed immunoprecipitation using the PC The resulting peptides were separated by reversedphase high pressure liquid chromatography and sub-1.0 M NaCl fraction from Daudi and Jurkat cell extracts. As expected, anti-TBP selectively precipitated the jected to microsequence analysis. The amino acid sequence of several peptides revealed striking similarities TAF II 105 subunit from Daudi cells but not from Jurkat cells (Figure 2A , lanes 4 and 5). These results strongly to the conserved C-terminal region of dTAF II 110 and its human homolog TAFII130 (N. Tanese, personal commusuggest that TAFII105 may be a novel TAF subunit that is only found associated with TFIID in selected cell types, nication; Figure 3 ). We therefore screened a Daudi cDNA library with a DNA fragment encompassing a highly consuch as highly differentiated B cells.
We hypothesized that a TFIID complex containing a served region of hTAFII130 under low stringency hybridization conditions. A pair of cDNA clones of approxiputative cell type-specific subunit would most likely participate in transcription of only a limited subset of genes, mately 2 kb corresponding to TAFII105 was obtained. These cDNAs contained a 3Ј poly(A) tail and a portion perhaps cell type-specific genes. Consequently, one might expect that only a subset of TFIID complexes of the coding region of TAF II 105. To isolate the remaining portions of TAF II 105, we screened several additional huwithin the cell will contain this subunit. Because silverstaining of proteins is notoriously nonquantitative, we man cDNA libraries with TAF II 105-specific probes. A pair of additional clones was isolated, one of 1.6 kb and the have attempted to determine the relative stoichiometry of TAF II 105 in the B cell TFIID complex by more reliable other of 3.6 kb, which overlapped the 3Ј region. DNA . The shaded boxes represent identical residues.
sequence analysis of the 3.6 kb insert revealed an open reading frame of 2406 bp that included all the peptide sequences obtained from the proteolytic digestions ( Figure 3A ). When this long cDNA was expressed in Sf9 cells with a flag-tag, the size of the recombinant protein was very similar to the endogenous TAF II 105 (see Figure  6A ). Since this clone does not contain a methionine residue that is preceded by a stop codon at its most 5Ј region, we concluded that this cDNA encodes most but probably not all of TAF II 105. We estimate that there may be 5-10 N-terminal residues missing from the full-length coding sequence. Nevertheless, we were able to use this slightly truncated cDNA to analyze further TAFII105 regulation and biochemical properties. Amino acid sequence deduced from the DNA sequence of TAFII105 revealed several regions with a high degree of similarity to hTAF II 130 and dTAF II 110. In particular, the C-terminal one-third of these proteins that includes domains involved in binding to other TAFs is highly conserved (68% identity and 87% homology). Interestingly, additional smaller patches of identity and some more extended regions of similarity between N-terminal region were quite diverged, suggesting that The finding that TAFII105 is present at high levels in Extensive analysis of the cloned TFIID subunits has indicated that formation of a stable TFIID complex involves TFIID complexes isolated from B cells but not from other cells tested suggests that its expression may also be multiple TAF-TBP and TAF-TAF interactions (Chen et al., 1994) . To identify the subunits in TFIID that contact cell type-specific. To address potential mechanisms of TAF II 105 regulation, we determined the levels of its TAF II 105, we performed a series of protein-protein interaction assays using immobilized flag-tagged TAF II 105 mRNA in different cell types by Northern blot analysis with a TAF II 105-specific probe. As a control, we hybridand 35 S-labeled in vitro translated TFIID subunits ( Figure  4) . These experiments indicate that TAF II 105 specifically ized identical samples with the ubiquitous hTAF II 130 probe ( Figure 5A ). Our analysis of TAF II 105 RNA revealed interacts with hTAF II 250 and dTAF II 150, the large subunit of TFIIA, and weakly with TBP. In contrast, TAF II 105 a single transcript of about 4.6 kb that is expressed at relatively invariant levels in all the cell types examined. did not appear to interact specifically with dTAF II 60, hTAFII70, TAFII60, dTAFII40, hTAFII32 (data not shown),
To confirm this finding further, we performed RNase protection assays. Similar amounts of RNA extracted dTAFII30␣, and dTAFII30␤ (Figure 4 ). Interestingly, a similar pattern of selective protein interactions has been from different cell types were hybridized with hTAFII105-or hTAFII250-specific probes followed by digestion with observed for dTAFII110 Weinzierl et al., 1993; Verrijzer et al., 1994; Yokomori et al., 1993a) , RNase A and RNase T1. Here again, the levels of protected TAFII105 transcripts from different cell types apsuggesting that these closely related TAFs have conserved interaction surfaces (i.e., C-terminus) for incorpeared comparable. Taken together, these data suggest that the regulation of TAF II 105 may be posttranscripporating into the TFIID complex (J.-L. Chen, K. Yokomori, F. Sauer, D. Wasserman, and R. T., unpublished tional, raising the possibility that the levels of TAF II 105 protein may be regulated in a cell type-specific manner. data). An exception to this pattern of TAF-TAF interaction is the ability of dTAF II 110 to bind TAF II 30␣ (Yokomori As a first step towards quantitating the amounts of TAF II 105 protein in different cells, we expressed the less et al., 1993b). In addition, it appears that dTAF II 110 and specific and suggest that the production of TAFII105 protein is cell type-specifically regulated.
Differential Effect of TAF II 105 Overexpression on Selected Promoters in B Cells
At present, cell type-specific activators that require TAF II 105 have not been identified. Thus, it is not practical or possible to test directly the potential cell typespecific coactivator properties of TAF II 105. However, it is possible to determine whether TAF II 105 has any effect on the transcription of selected genes in B cells by relying on the phenomenon of "squelching" (Gill and Ptashne, 1988; Berger et al., 1990; Kelleher et al., 1990 ). In our case, the overexpression of a coactivator rather than an activator should inhibit the transcription of specific genes that require the coactivator. To test whether TAF II 105 has any transcriptional function and is able to moter as well as a control template carrying the cytomegalovirus (CMV) promoter. Each of these reporter constructs was cotransfected with increasing amounts conserved N-terminal portion of the protein in Escheof expression plasmids bearing TAFII105. Overexpresrichia coli and raised polyclonal antibodies against sion of TAF II 105 in BJAB cells efficiently inhibited tranthis region of TAF II 105. These anti-TAF II 105 antibodies scription from both of the Kappa enhancer/promoter specifically recognized a 105 kDa polypeptide presconstructs (3-5-fold; Figure 7 ). By contrast, the expresent in Daudi nuclear extract as well as recombinant sion of TAF II 105 had no significant effect on J chain TAF II 105 produced in Sf9 cells ( Figure 6A ). As expected, promoter/enhancer transcription nor on the CMV proanti-TAF II 105 antibodies can also immunoprecipitate moter activity in these same cells. As might be expected TAFII105 together with all the core TFIID subunits, includof a typical squelching reaction, a truncated version ing its homolog TAF II 130, from Daudi extracts (Figure of TAF II 105 lacking the C-terminal TAF-TAF interaction 6B), indicating that both TAF II 105 and TAF II 130 might be domain but containing the putative activator interaction present in the same complex. To measure the relative domain was also able to inhibit transcription from the Kappa promoter/enhancer constructs (data not shown). levels of TAF II 105 protein expressed in different cell These results suggest that TAFII105 most likely functions types, similar amounts of nuclear extracts from different as a coactivator or target for a subset of activators cell types were subjected to Western blot analysis using responsible for transcription of genes in B cells. TAFII105 and TBP antibodies. As shown in Figures 6C  and 6D , the levels of TAF II 105 protein were 10-20-fold higher in Daudi B cells than in non-B cells, suggesting Discussion that the cell type-specific regulation of TAF II105 may be at the level of protein expression. The anti-TAF II 105
It has been well established that combinatorial arrays antibodies were also used to compare the levels of of gene-specific DNA binding factors (i.e., activators, TAF II105 associated with affinity-purified TFIID isolated repressors, and associated cofactors) govern the princifrom Daudi, Jurkat, and SK-N cells ( Figure 6E ). These pal means by which cell type-specific gene expression antibodies specifically detected TAF II105 in Daudi TFIID is regulated in animal cells. In this study we present but not in Jurkat and SK-N TFIID complex. We verified evidence that the basal transcriptional apparatus may the fact that the level of TBP in the TFIID complex was also incorporate cell type-specific components and similar by Western blotting with TBP antibodies (data thereby provide additional mechanisms for directing tisnot shown). Next, we looked at TAFII105 protein levels sue-specific transcription. We have identified, purified, in another differentiated human B cell line, BJAB, and cloned, and partially characterized a novel 105 kDa huin normal human tissue extracts such as B lymphocytes, man TAF that is found in TFIID isolated from differentiliver, colon, and brain by Western blotting ( Figures 6F ated B cells but essentially undetectable in TBP-TAF and 6G). As expected, TAF II 105 was easily detected in complexes purified from a variety of other cell types BJAB and normal B lymphocytes but not in HeLa and representing different tissues. the other normal tissues. Taken together, these results
Previous experiments indicate that transcriptional activation by distinct classes of enhancer-binding proteins add support to the notion that TAF II 105 is cell type- 7) and a dilution series of Daudi extract (lanes 1-4) using anti-TAF II105 antibodies (lanes 1-7) . (E) Anti-TBP affinity-purified TFIID complexes isolated from Daudi, Jurkat, and SK-N cells were resolved on SDS-PAGE and subjected to Western blot analysis using anti-TAF II105 antibodies. (F) Western blot analysis of nuclear extract prepared from HeLa and BJAB cells using either TAF II105 or TBP antibodies as indicated. (G) Total cell extracts from enriched human B lymphocytes (30 g), liver (75 g), colon (75 g), and brain (75 g) were subjected to Western blot analysis using affinity-purified TAF II105 antibodies. The position of TAFII105 is indicated by an arrow.
can be mediated by subsets of TBP-TAF complexes TAFII130/110 family of coactivators are unable to function in yeast via the glutamine-rich activation domains and that coactivator function most likely involves direct interactions between TAFs and activation domains of (Attardi and Tjian, 1993; Kü nzler et al., 1994; Ponticelli et al., 1995; G. Gill and R. T., unpublished data) . It is transcription factors (Chen et al., 1994; Jacq et al., 1994; Chiang and Roeder, 1995; Thut et al., 1995; Sauer et al., possible that this class of TAFs that includes the cell type-specific TAF II 105 evolved to accommodate the 1995). For example, glutamine-rich activation domains of human SP1 and Drosophila bicoid were shown to more elaborated needs of transcriptional regulation in metazoans. contact directly human TAF II 130 or its Drosophila homolog dTAF II 110 to direct transcriptional activation in vitro
The primary amino acid sequence of hTAF II 105 and related members of this family of TAFs (TAFII130 and (Chen et al., 1994; Sauer et al., 1995; N. Tanese, personal communication) . Here we report that human TAFII105 is dTAFII110) reveal the presence of two distinct domains: a highly conserved C-terminal region and an N-terminal highly related to these two core TAFs, hTAFII130 and dTAFII110, suggesting that these three subunits of TFIID domain containing significantly more diverged sequences interspersed with small patches of homology. represent different members of a family of TAFs that can serve as transcriptional coactivators. Although many of Recent experiments with dTAFII110 mutants suggest that the conserved C-terminal region is responsible for the TAFs first identified in Drosophila and human TFIID have recently also been found in yeast, thus far no homointeracting with TAF II 250 and TFIIA (F. Sauer, D. Wasserman, and R. T., unpublished data), whereas the less log of dTAF II 110 or hTAF II 130 has been isolated from yeast (Poon et al., 1995; Reese et al., 1994) . As one might conserved N-terminal domain of TAF II 110 contains interaction surfaces that bind to activators . expect, activators such as human SP1 and Drosophila bicoid that use a glutamine-rich domain to target the Since many of the contacts between hTAF II 105 and BJAB cells were transfected with 2 g of the indicated luciferase reporter plasmids together with increasing amounts of TAF II 105 expression plasmid (0, 2, and 10 g) and 2 g of CMV-␤gal. The normalized luciferase activity of the reporter plasmids in the absence of TAF II105 (lanes 1, 4, 7, and 10) is arbitrarily set as 100%.
dTAFII110 with the other TFIID subunits are conserved, nonconserved N-terminal sequences of TAFII105 have evolved to direct interactions with certain activators that it is likely that the homologous C-terminal domain of TAFII105 is responsible for directing these TAF-TAF and are not targeted by human TAFII130, possibly cell typespecific activators. However, we also expect to find acti-TAF-TBP interactions. Therefore, in differentiated B cells one might expect to find TFIID complexes that vators that can interact with both TAF II 105 and TAF II 130, since there are regions of the putative N-terminal coacticontain either TAF II 105 or TAF II 130 but perhaps not both. However, when we isolated TFIID complexes using eivator domain that are conserved between members of this family of TAFs. In addition, the conserved C-terminal ther anti-TAF II 105 or anti-TAF II 130 antibodies from B cells, we found both polypeptides in the same complex.
domain may also contain coactivator functions that could be targeted by common activators. It is possible that in these TFIID complexes, each of the related TAFs uses a different portion of its potential Human TFIID isolated from B cells contain substoichiometric amounts of TAFII105, suggesting that only a interaction surfaces to assemble into TFIID. An alternative explanation was provided by the finding that small proportion of the TBP-TAF complexes in these cells contain this tissue-specific subunit. This finding is TAFII105 and TAFII110 could interact directly with each other (R. D. and R. T., unpublished data), suggesting consistent with the notion that only a limited number of genes, perhaps cell type-specific genes, are targeted that TFIID from B cells may contain either homodimers of human TAF II 130 or heterodimers of human TAF II 105 by TFIID complexes containing TAF II 105. Consequently, only a limited set of genes that are expressed in B cells and 130. It is also possible that TFIID can exist as dimers (Coleman et al., 1995; Taggart and Pugh, 1996) and that are expected to recruit TFIID complexes containing TAF II 105. It is also possible that TAF II 105-containing therefore, TFIID complexes containing both TAF II 105 and TAF II 130 would be coprecipitated.
TFIID complexes will display other biochemical properties distinct from core TFIID, such as an altered DNA By analogy to the functional domains of dTAF II 110 and hTAF II 130, the N-terminal region of human TAF II 105 binding specificity that is influenced by the presence of TAF II 105. Once cell type-specific enhancers and activais predicted to interact with activation domains. We anticipate that a TFIID complex containing TAFII105 will tors that require human TAFII105 are identified, it should be possible to address these important issues. play some role in the transcription of cell type-specific genes, perhaps by directly contacting a subset of B cell
Although we screened for putative cell type-specific TAFs in TFIID complexes isolated from several different enhancer-binding proteins to mediate transcription. It will be of interest in the future to identify putative cell cell types, we have thus far failed to identify any additional cell type-specific subunits other than TAFII105. type-specific activators that will require the presence of TAF II 105 to potentiate transcriptional activation. In Our ability to detect TAF II 105 initially was, in part, aided by the fortuitous property of this protein to stain effithis respect, it is reassuring that overexpression either of full-length TAF II 105 or of a truncated version conciently with silver. We do not believe that TAF II 105 will be the only substoichiometric cell type-specific subunit taining the putative activator interaction domain (N-terminal region) is able to squelch differentially transcripassociated with TFIID. Instead, we anticipate that a more systematic screen will reveal the presence of additional tion of selected genes in B cells. It is likely that the by 50 mM glycine (pH 2.5) and 150 mM NaCl and precipitated with cell type-specific components of the TFIID complex. trichloroacetic acid containing deoxycholate (4 mg/ml). The TAFs To detect additional cell type-specific and potentially were resolved by SDS-PAGE, transferred to nitrocellulose memdevelopmentally regulated TAFs, it will be necessary to brane, and stained with ponceau S (Sigma). The band corresponding devise more sensitive detection methods, especially if to TAF II 105 was excised and digested with either trypsin or V8 protethese proteins are substoichiometric and of small moases, and peptides eluted from the membrane were resolved by reversed-phase high pressure liquid chromatography and subjected lecular mass. Total cytoplasmic RNA samples were prepared from cultured cells according to the procedure that has been described (Gough, 1988 PIPES (pH 6.7), 350 mM NaCl, 1 mM EDTA, and 80% formamide. RNase A (40 g/ml) and RNase T1 (2 g/ml) were added, and digesExperimental Procedures tion was carried out at 30ЊC for 30 min. The reactions were terminated by the addition of 50 g of proteinase K and 10 l of SDS Antibodies and Immunoprecipitations and incubation at 37ЊC for 30 min. After phenol-chloroform extracNuclear extracts from different cell types were prepared and fraction and ethanol precipitation, the samples were resolved on 6% tionated by PC P11 column as described (Pugh and Tjian, 1990;  denaturing polyacrylamide gel and autoradiographed. Tanese et al., 1991) . Polyclonal anti-TBP antibodies raised against recombinant hTBP were described (Tanese et al., 1991) . The antiExpression of TAFII105 Protein bodies were affinity-purified using TBP-coupled affinity resins.
A 3.6 kb NotI fragment containing the entire sequences of the long Monoclonal anti-TAF II130 antibody IA5 was described (Ruppert et cDNA was subcloned into the NotI site of the vector pVL1392. Next, al., 1993) . TAF II105 polyclonal antibodies were raised against recoma 3.1 kb NdeI fragment containing the coding region was subcloned binant protein corresponding to amino acids 1-552 produced in into the baculovirus expression vector pVLSG2Flag in NdeI site. bacteria with 6 histidine-tag. The inclusion bodies containing overRecombinant baculovirus was generated as described (Dikstein et expressed TAFII105 were dissolved in 6 M urea, purified by Ni ϩ al., 1996). Crude extracts from cells expressing flag-TAFII105 were agarose resin, and resolved on SDS-PAGE, and TAF II 105 protein was bound to flag antibody beads (Kodak) in 0.5 M KCl HEMG buffer excised and injected into rabbits. Immunoprecipitations of TFIID for 2-3 hr. After five washes with the same buffer, a small portion complex by affinity-purified TBP antibodies, anti-TAF II 130 (IA5), and was analyzed by SDS-PAGE. Before the interaction assays, the anti-TAF II105 were carried with TFIID-enriched PC fractions or dibeads were washed twice with 0.1 M KCl HEMG. rectly from nuclear extracts essentially as described (Tanese et al., 1991) . Briefly, 400 g of 1.0 M NaCl PC fraction or 5 mg of nuclear In Vitro Binding Experiments extracts in HEMG buffer (20 mM HEPES [ph 7.9], 100 mM KCl, 12.5 35 S-labeled TAFs were synthesized in vitro by T7 RNA polymerase mM MgCl 2, 0.2 mM EDTA, 0.1% NP-40, 1 mM dithiothreitol, 0.2 mM and rabbit reticulocytes lysate and incubated with flag beads or phenylmethylsulfonyl fluoride) were incubated with antibodies and with TAF II 105 coupled to flag beads in 0.1 M KCl HEMG buffer for protein A sepharose beads at 4ЊC for 2-3 hr. The immune complexes 2 hr at 4ЊC. The beads were washed five times with the same buffer, were washed with HEMG buffer five times and eluted either by 1 M and the bound proteins were eluted by 5 min boiling in protein guanidine-HCl followed by trichloroacetic acid precipitation or by sample buffer followed by SDS-PAGE and autoradiography. 5 min boiling in SDS-PAGE protein sample buffer.
For the Western blot analysis shown in Figure 6G , premade extracts from normal human liver, colon, and brain were purchased Plasmids and Transfection kEkPLuc and Ek3ЈkPLuc were generated by replacing a BamHI fragfrom Clontech, and enriched B lymphocytes extract was a gift from Dr. T. Hoey (Tularik Inc.) . ment containing the CAT gene and SV40 poly A signal of kEkPCAT (Atchison and Perry, 1987) and Ek3ЈkPCAT (a gift from Dr. M. Atchison) with a BamHI-BglII fragment containing the luciferase gene Cloning of TAF II 105 cDNA Daudi cells nuclear extracts were prepared from 2000 l of culture, and SV40 pA signal from pGL2 basic vector (Promega). pGL2JEJP was a gift from Drs. K. Chang and M. Koshland. CMV-TAF II105 and TFIID-enriched fraction was obtained by PC column (Tanese et al., 1991) . TFIID was immunopurified directly from PC 1.0 M NaCl was constructed by inserting a BamHI-BglII fragment containing TAF II105 cDNA into BamHI site of the pCMX vector. BJAB cells were fraction using cross-linked anti-TBP resin, and the TAFs were eluted transfected by the DEAE-Dextran method. In all the transfections, W. (1994) . Functional differences between mammalian transcription activation domains at the yeast GAL1 promoter. EMBO J. 13, the total amount of CMV promoter was adjusted to constant levels with the pCMX plasmid. Each experiment was repeated 2-4 times 641-645. in duplicate. Luo, Y., and Roeder, R.G. (1995) . Cloning, functional characterization, and mechanism of action of the B cell-specific transcriptional
